Participate in the ALXN-1720-MG-301
Clinical Trial Today

Interested in participating in an Myasthenia Gravis Clinical Trial?

Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis 

Study Description 

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR). 

Eligibility Criteria 

  • Ages Eligible for Study:  18 Years and older   (Adult, Older Adult) 

  • Sexes Eligible for Study:  All 

  • Accepts Healthy Volunteers:  No 

Inclusion Criteria: 

  • Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV. 

  • Positive serological test for autoantibodies against AChR. 

Exclusion Criteria: 

  • History of thymectomy or any other thymic surgery within 12 months prior to Screening 

  • Untreated thymic malignancy, carcinoma, or thymoma 

  • History of Neisseria meningitidis infection 

  • Pregnancy, breastfeeding, or intention to conceive during the course of the study. 

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please sign up below.







“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

  • Our mission

    To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.

  • Our vision

    To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research

  • Our future

    Genge Partners will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.

Our facilities:

Genge Partners @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA

Genge Partners @ Pointe Claire
955 Boul Saint-Jean, Suite 212
Pointe-Claire, QC H9R 5K3

 

© 2022 Genge Partners Inc. All rights reserved | Confidentiality policy